SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Alles Mark J

(Last) (First) (Middle)
C/O CELGENE CORPORATION
86 MORRIS AVENUE

(Street)
SUMMIT NJ 07901

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CELGENE CORP /DE/ [ CELG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
02/06/2015
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/06/2015 M 4,922 A $81.555 71,064 D
Common Stock 02/06/2015 M 4,434 A $74.3 75,498 D
Common Stock 02/06/2015 M 1,719 A $27.275 77,217 D
Common Stock 02/06/2015 M 444 A $30.74 77,661 D
Common Stock 02/06/2015 M 1,290 A $26.17 78,951 D
Common Stock 02/06/2015 M 2,580 A $28.94 81,531 D
Common Stock 02/06/2015 M 41,335 A $29.75 122,866 D
Common Stock 02/06/2015 M 1,290 A $25.765 124,156 D
Common Stock 02/06/2015 M 4,688 A $36.96 128,844 D
Common Stock 02/06/2015 M 3,122 A $36.465 131,966 D
Common Stock 02/06/2015 M 6,243 A $34.7 138,209 D
Common Stock 02/06/2015 M 6,243 A $36.675 144,452 D
Common Stock 02/06/2015 M 13,125 A $40.22 157,577 D
Common Stock 02/06/2015 M 3,122 A $49.475 160,699 D
Common Stock 02/06/2015 M 4,434 A $59.235 165,133 D
Common Stock 02/06/2015 M 4,434 A $71.33 169,567 D
Common Stock 02/06/2015 M 4,434 A $78.115 174,001 D
Common Stock 02/06/2015 S 117,099 D $120.677(1) 56,902 D
Common Stock 02/06/2015 A 30,404(2) A $0.00 87,306 D
Common Stock 02/06/2015 F 13,666 D $118.75 73,640 D
Common Stock 5,461 I 401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $81.555 02/06/2015 M 4,922 (3) 12/02/2023 Common Stock 4,922 $0.00(4) 14,764 D
Stock Option (right to buy) $74.3 02/06/2015 M 4,434 (3) 02/03/2024 Common Stock 4,434 $0.00(4) 13,302 D
Stock Option (right to buy) $27.275 02/06/2015 M 1,719 (3) 10/13/2019 Common Stock 1,719 $0.00(4) 573 D
Stock Option (right to buy) $30.74 02/06/2015 M 444 (3) 04/13/2020 Common Stock 444 $0.00(4) 148 D
Stock Option (right to buy) $26.17 02/06/2015 M 1,290 (3) 07/13/2020 Common Stock 1,290 $0.00(4) 430 D
Stock Option (right to buy) $28.94 02/06/2015 M 2,580 (3) 10/12/2020 Common Stock 2,580 $0.00(4) 860 D
Stock Option (right to buy) $29.75 02/06/2015 M 41,335 (3) 12/27/2020 Common Stock 41,335 $0.00(4) 5,333 D
Stock Option (right to buy) $25.765 02/06/2015 M 1,290 (3) 01/31/2021 Common Stock 1,290 $0.00(4) 430 D
Stock Option (right to buy) $36.96 02/06/2015 M 4,688 (3) 03/01/2022 Common Stock 4,688 $0.00(4) 9,852 D
Stock Option (right to buy) $36.465 02/06/2015 M 3,122 (3) 04/30/2022 Common Stock 3,122 $0.00(4) 9,366 D
Stock Option (right to buy) $34.7 02/06/2015 M 6,243 (3) 07/30/2022 Common Stock 6,243 $0.00(4) 10,407 D
Stock Option (right to buy) $36.675 02/06/2015 M 6,243 (3) 10/31/2022 Common Stock 6,243 $0.00(4) 10,407 D
Stock Option (right to buy) $40.22 02/06/2015 M 13,125 (3) 12/17/2022 Common Stock 13,125 $0.00(4) 21,875 D
Stock Option (right to buy) $49.475 02/06/2015 M 3,122 (3) 01/28/2023 Common Stock 3,122 $0.00(4) 11,508 D
Stock Option (right to buy) $59.235 02/06/2015 M 4,434 (3) 04/29/2023 Common Stock 4,434 $0.00(4) 19,216 D
Stock Option (right to buy) $71.33 02/06/2015 M 4,434 (3) 07/29/2023 Common Stock 4,434 $0.00(4) 13,302 D
Stock Option (right to buy) $78.115 02/06/2015 M 4,434 (3) 10/28/2023 Common Stock 4,434 $0.00(4) 13,302 D
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person pursuant to a rule 10b5-1 plan in multiple transactions at prices ranging from $118.98 to $121.70, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
2. Represents shares of common stock relating to the 2012-2014 Long Term Incentive Plan and issued under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013).
3. The option was fully exercisable.
4. The option was issued pursuant to the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013).
Remarks:
President and Chief Operating Officer
/s/ Robert J. Hugin __________________________ Robert J. Hugin, Attorney-in-Fact 02/10/2015
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.